Zetouni Nikolas C., Sergi Consolato M.
Department of Laboratory Medicine and Pathology, University of Alberta Hospital, Walter C. Mackenzie Centre, Edmonton, AB, Canada
Department of Orthopedics, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan, Hubei, China
Since its first description in 1921, Ewing sarcoma has been the subject of several morphologic and genetic investigations. Currently, the overall survival for localized Ewing sarcoma is 65–70%. However, in patients presenting with metastatic disease, the overall survival is poor, being in the range of 20–30%. There are several unknown features of Ewing sarcoma, such as its cell of origin, genetic background, chemotherapy resistance, and abnormal presentation sites, among others. A better understanding of the molecular basis of the development of Ewing sarcoma is needed to help improve survival, especially in metastatic/resistance cases. In this chapter, we provide an overview of the features of metastatic Ewing sarcoma.
自1921年首次被描述以来,尤因肉瘤一直是多项形态学和遗传学研究的对象。目前,局限性尤因肉瘤的总体生存率为65%至70%。然而,对于出现转移性疾病的患者,总体生存率很低,在20%至30%的范围内。尤因肉瘤有几个未知特征,例如其起源细胞、遗传背景、化疗耐药性以及异常的发病部位等。需要更好地了解尤因肉瘤发生发展的分子基础,以帮助提高生存率,尤其是在转移性/耐药性病例中。在本章中,我们概述了转移性尤因肉瘤的特征。